Form 4: Vera Therapeutics Director Beth C. Seidenberg Acquires Stock Options

Director Beth C. Seidenberg acquired stock options for 14,000 shares of Vera Therapeutics, Inc. at an exercise price of $42.69 on May 15, 2024.

Summary

• On May 15, 2024, Beth C. Seidenberg, a director of Vera Therapeutics, Inc., acquired stock options for 14,000 shares.
• The exercise price for these options is $42.69 per share.
• The options vest fully on the earlier of the first anniversary of the grant date or the date of the company's 2025 annual stockholder meeting, contingent upon continuous service.
• The options also vest fully upon a change in control, subject to continuous service through that date.
• The expiration date for the options is May 14, 2034.
• Following the transaction, Seidenberg directly owns derivative securities for 14,000 shares.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing an insider transaction. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.

Future Outlook

The vesting of the options is contingent upon continued service and may also occur upon a change in control, indicating potential future alignment with company performance and strategic events.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the holdings and transactions of company insiders, allowing investors to monitor management's alignment with shareholder interests.

Stakeholder Impact

• The transaction provides transparency to shareholders regarding insider activity.
• The vesting conditions incentivize the director to remain with the company and contribute to its success.

Key Dates